As the battle against SARS-CoV-2 continues, it’s time for the COVID-19 Evidence Accelerator to return to an earlier focus for this Thursday’s meeting (3pmET) -- exploring therapeutic interventions for active infection.

Join us for a look at the data on monoclonal antibody treatment from two major health systems (Intermountain Healthcare and the Mayo Clinic). What can we do to increase uptake of these interventions? What can we learn about ideal treatment windows from current use? Join us to explore these and other questions—and contribute to the discussion.